Envestnet Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $447K | Sell |
12,057
-171
| -1% | -$5.19K | ﹤0.01% | 4163 |
|
|
2026
Q1 | $414K | Sell |
12,228
-507
| -4% | -$14.4K | ﹤0.01% | 4064 |
|
|
2025
Q4 | $347K | Buy |
12,735
+3,312
| +35% | +$116K | ﹤0.01% | 3938 |
|
|
2025
Q3 | $378K | Sell |
9,423
-677
| -7% | -$25.5K | ﹤0.01% | 3932 |
|
|
2025
Q2 | $336K | Sell |
10,100
-12,453
| -55% | -$377K | ﹤0.01% | 3955 |
|
|
2025
Q1 | $661K | Sell |
22,553
-2,252
| -9% | -$74.7K | ﹤0.01% | 3445 |
|
|
2024
Q4 | $815K | Buy |
24,805
+795
| +3% | +$37.3K | ﹤0.01% | 3293 |
|
|
2024
Q3 | $1.07M | Sell |
24,010
-521
| -2% | -$23.7K | ﹤0.01% | 3100 |
|
|
2024
Q2 | $1.06M | Buy |
24,531
+114
| +0.5% | +$4.11K | ﹤0.01% | 3006 |
|
|
2024
Q1 | $714K | Buy |
24,417
+8,302
| +52% | +$222K | ﹤0.01% | 3238 |
|
|
2023
Q4 | $359K | Sell |
16,115
-2,947
| -15% | -$66K | ﹤0.01% | 3510 |
|
|
2023
Q3 | $472K | Buy |
19,062
+1,314
| +7% | +$34.8K | ﹤0.01% | 3294 |
|
|
2023
Q2 | $503K | Buy |
17,748
+2,000
| +13% | +$49.8K | ﹤0.01% | 3204 |
|
|
2023
Q1 | $362K | Buy |
15,748
+953
| +6% | +$25.3K | ﹤0.01% | 3352 |
|
|
2022
Q4 | $415K | Buy |
14,795
+278
| +2% | +$7.83K | ﹤0.01% | 3203 |
|
|
2022
Q3 | $411K | Buy |
14,517
+3,922
| +37% | +$105K | ﹤0.01% | 3139 |
|
|
2022
Q2 | $235K | Buy |
10,595
+2,700
| +34% | +$61K | ﹤0.01% | 3496 |
|
|
2022
Q1 | $230K | Buy |
+7,895
| New | +$241K | ﹤0.01% | 3608 |
|
|
2021
Q4 | – | Sell |
-4,573
| Closed | -$211K | – | 3865 |
|
|
2021
Q3 | $211K | Sell |
4,573
-1,573
| -26% | -$76K | ﹤0.01% | 3479 |
|
|
2021
Q2 | $339K | Buy |
6,146
+2,157
| +54% | +$121K | ﹤0.01% | 3215 |
|
|
2021
Q1 | $206K | Buy |
+3,989
| New | +$198K | ﹤0.01% | 3326 |
|
|
2020
Q3 | – | Sell |
-4,441
| Closed | -$238K | – | 3097 |
|
|
2020
Q2 | $238K | Buy |
+4,441
| New | +$206K | ﹤0.01% | 2798 |
|
|
2020
Q1 | – | Sell |
-5,109
| Closed | -$244K | – | 2962 |
|
|
2019
Q4 | $244K | Buy |
+5,109
| New | +$193K | ﹤0.01% | 2824 |
|
|
2018
Q3 | – | Sell |
-276
| Closed | -$23K | – | 1262 |
|
|
2018
Q2 | $23K | Buy |
276
+14
| +5% | +$1.22K | ﹤0.01% | 2393 |
|
|
2018
Q1 | $21K | Buy |
262
+50
| +24% | +$3.87K | ﹤0.01% | 2353 |
|
|
2017
Q4 | $12K | Buy |
212
+27
| +15% | +$1.7K | ﹤0.01% | 2592 |
|
|
2017
Q3 | $12K | Buy |
185
+65
| +54% | +$3.9K | ﹤0.01% | 2558 |
|
|
2017
Q2 | $6K | Buy |
120
+23
| +24% | +$1.18K | ﹤0.01% | 2791 |
|
|
2017
Q1 | $5K | Buy |
97
+76
| +362% | +$3.64K | ﹤0.01% | 2889 |
|
|
2016
Q4 | $1K | Buy |
+21
| New | +$1.1K | ﹤0.01% | 3018 |
|
|
2016
Q3 | – | Sell |
-2,542
| Closed | -$106K | – | 2898 |
|
|
2016
Q2 | $106K | Sell |
2,542
-227
| -8% | -$11.2K | ﹤0.01% | 2400 |
|
|
2016
Q1 | $112K | Buy |
2,769
+680
| +33% | +$29.1K | ﹤0.01% | 2347 |
|
|
2015
Q4 | $136K | Buy |
2,089
+142
| +7% | +$9.31K | ﹤0.01% | 2236 |
|
|
2015
Q3 | $137K | Buy |
1,947
+142
| +8% | +$13.9K | ﹤0.01% | 2211 |
|
|
2015
Q2 | $201K | Buy |
+1,805
| New | +$194K | ﹤0.01% | 2134 |
|
Other funds holding AGIO
FCM
LCM
AC
EAM
NAMI
Envestnet Asset Management's AGIO Position: Q2 2026 in Review
Envestnet Asset Management reduced its Agios Pharmaceuticals (AGIO) stake by 1.4% in Q2 2026, selling an estimated $5.19K and leaving 12,057 shares worth $447K. The position accounts for ﹤0.01% of the portfolio, ranked #4163.
Envestnet Asset Management first reported a position in AGIO in Q2 2015 and has held it in 35 quarters since. The position peaked at $1.07M in Q3 2024. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.
- Envestnet Asset Management held 12,057 shares of Agios Pharmaceuticals worth $447K as of Q2 2026.
- Envestnet Asset Management sold 171 Agios Pharmaceuticals shares in Q2 2026, an estimated $5.19K.
- Agios Pharmaceuticals made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #4163 holding.
- Envestnet Asset Management first reported a position in Agios Pharmaceuticals in Q2 2015 and has held it in 35 quarters since.
- Envestnet Asset Management's Agios Pharmaceuticals position peaked at $1.07M in Q3 2024.
- 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.
Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.